Integra LifeSciences Holdings
$ 19.01
0.64%
21 Jul - close price
- Market Cap 1,469,583,000 USD
- Current Price $ 19.01
- High / Low $ 19.30 / 18.61
- Stock P/E N/A
- Book Value 13.39
- EPS -6.47
- Next Earning Report 2026-07-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.03 %
- ROE -0.39 %
- 52 Week High 20.26
- 52 Week Low 8.70
About
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, limb reconstruction, orthopedics, and general surgery. The company is headquartered in Princeton, New Jersey.
Analyst Target Price
$18.62
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-26 | 2025-10-30 | 2025-07-31 | 2025-05-05 | 2025-02-25 | 2024-11-04 | 2024-07-29 | 2024-05-06 | 2024-02-28 | 2023-10-25 | 2023-07-26 |
| Reported EPS | 0.54 | 0.83 | 0.54 | 0.45 | 0.41 | 0.97 | 0.41 | 0.63 | 0.55 | 0.89 | 0.76 | 0.71 |
| Estimated EPS | 0.4 | 0.79 | 0.43 | 0.43 | 0.43 | 0.8554 | 0.39 | 0.62 | 0.55 | 0.9 | 0.78 | 0.57 |
| Surprise | 0.14 | 0.04 | 0.11 | 0.02 | -0.02 | 0.1146 | 0.02 | 0.01 | 0 | -0.01 | -0.02 | 0.14 |
| Surprise Percentage | 35% | 5.0633% | 25.5814% | 4.6512% | -4.6512% | 13.3972% | 5.1282% | 1.6129% | 0% | -1.1111% | -2.5641% | 24.5614% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-29 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.48 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $6.37 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IART
2026-07-16 13:42:24
Integra LifeSciences Holdings Corporation announced it will release its second-quarter 2026 financial results on July 29, 2026, before the market opens. Following the release, the management team will host a conference call at 8:30 a.m. ET to discuss the results and outlook, with a live webcast available on the company's investor website. This announcement comes after BMO Capital initiated coverage on Integra Lifesciences with a Market Perform rating and a $19 price target.
2026-07-16 11:42:24
Integra LifeSciences (NASDAQ: IART) announced that it will release its second-quarter 2026 financial results on Wednesday, July 29, 2026, before the market opens. Management will host an earnings conference call at 8:30 a.m. ET, which will be accessible via live webcast and replay on the company's investor relations website. Following this announcement, the stock saw a positive market reaction, gaining 5.38% and adding approximately $79 million to its valuation.
2026-07-16 11:42:24
Integra LifeSciences Holdings Corporation will release its second quarter 2026 financial results on Wednesday, July 29, 2026, before the market opens. Following the release, the management team will host a conference call at 8:30 a.m. ET, with a live webcast available on the company's investor relations website. A webcast replay will also be accessible on the website after the call.
2026-07-15 14:12:56
Integra LifeSciences Holdings (IART) stock has reached a new 52-week high of $18.93, representing a 54.13% increase over the past year and a 113% surge from its 52-week low. This milestone follows the company's strong first-quarter 2026 financial results, which exceeded analyst expectations, and positive analyst coverage, including an upgrade to Buy by Argus. InvestingPro analysis indicates the stock remains undervalued despite its recent gains.
2026-07-12 18:09:54
This article lists various ETFs that invest in Integra LifeSciences Holdings Corporation (IL3) stocks, sorted by market value. It provides key details for each ETF, such as market value, weight of IL3 in the fund, issuer, management style, focus, expense ratio, AUM, price change, and 3-year NAV total return. The ETFs predominantly focus on small-cap and healthcare sectors, making investing in IL3 more accessible while offering diversification.
2026-07-10 05:09:00
BMO Capital initiated coverage on Integra LifeSciences Holdings Corp. (NASDAQ:IART) with a Market Perform rating and a $19.00 price target. The firm highlighted the return of CEO Essig, strong Q1 2026 earnings, and record Integra Skin production as positive signs. Despite a 46% year-to-date rise in shares, BMO Capital notes that key catalysts are still ahead for the company, which has seen three years of guidance cuts.
